Date of submission: 27/05/2022

Prostate Adenocarcinoma

TM00298

Model characterisation

Provided by

The Jackson laboratory

View data at JAX Contact JAX

License: EMBL-EBI

Patient / Tumour Metadata

Patient Sex
male
Patient Age
Not Provided
Patient Ethnicity
Hispanic
Tumour Type
Primary
Cancer Grade
GG1:5,GG2:5,GG3:
Cancer Stage
Not provided
Primary Site
prostate gland
Collection Site
prostate gland

PDX model engraftment

PDX model engraftment
HOST STRAIN NAME	SITE	TYPE	MATERIAL	MATERIAL STATUS	PASSAGE
nsg	Not Provided	Heterotopic	Surgical Resection (fragment)	Not Provided	1

Model quality control

Model quality control
TECHNIQUE	DESCRIPTION	PASSAGE
Histology, Ki67 Ihc, Cd45 Ihc, Str Analysis	The histology of the engrafted tumor retains morphologic features of the primary patient tumor as assessed by a Board Certified Pathologist. IHC for human Ki67 validates that the tumor cells are actively dividing and are of human origin. IHC for CD45 and cytokeratin (AE1/AE3) rules out a xenograft-associated lymphocytic tumor. STR analysis validates provenance of engrafted tumor.	Not provided

Immune markers

Immune markers
SAMPLE ID	MMR	MSI	Mutations per mb	TMB	Ploidy
PR1996F336P0	Not provided	High	Not provided	29.88	Not provided

Model treatment

Model treatment
DRUG	DOSE	PASSAGE	RESPONSE
Cisplatin ChEMBL PubChem	2.0 mg/kg	1	Progressive Disease
Docetaxel ChEMBL PubChem	10.0 mg/kg	1	Progressive Disease
Dextrose Monohydrate PubChem	5.0 ml/kg	1	Progressive Disease